OBJECTIVE: To assess longitudinal tremor outcomes with ventral intermediate nucleus deep brain stimulation (VIM DBS) in patients with dystonic tremor (DT) and to compare with DBS outcomes in essential tremor (ET). METHODS: We retrospectively investigated VIM DBS outcomes for 163 patients followed at our center diagnosed with either DT or ET. The Fahn-Tolosa-Marin tremor rating scale (TRS) was used to assess change in tremor and activities of daily living (ADL) at 6 months, 1 year, 2-3 years, 4-5 years, and ≥6 years after surgery. RESULTS: Twenty-six patients with DT and 97 patients with ET were analyzed. Compared to preoperative baseline, there were significant improvements in TRS motor up to 4-5 years (52.2%; p = 0.032) but this did not reach statistical significance at ≥6 years (46.0%, p = 0.063) in DT, which was comparable to the outcomes in ET. While the improvements in the upper extremity tremor, head tremor, and axial tremor were also comparable between DT and ET throughout the follow-up, the ADL improvements in DT were lost at 2-3 years follow-up. CONCLUSION: Overall, tremor control with VIM DBS in DT and ET was comparable and remained sustained at long term likely related to intervention at the final common node in the pathologic tremor network. However, the long-term ADL improvements in DT were not sustained, possibly due to inadequate control of concomitant dystonia symptoms. These findings from a large cohort of DT indicate that VIM targeting is reasonable if the tremor is considerably more disabling than the dystonic features. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that VIM DBS improves tremor in patients with DT or ET.
OBJECTIVE: To assess longitudinal tremor outcomes with ventral intermediate nucleus deep brain stimulation (VIMDBS) in patients with dystonic tremor (DT) and to compare with DBS outcomes in essential tremor (ET). METHODS: We retrospectively investigated VIMDBS outcomes for 163 patients followed at our center diagnosed with either DT or ET. The Fahn-Tolosa-Marin tremor rating scale (TRS) was used to assess change in tremor and activities of daily living (ADL) at 6 months, 1 year, 2-3 years, 4-5 years, and ≥6 years after surgery. RESULTS: Twenty-six patients with DT and 97 patients with ET were analyzed. Compared to preoperative baseline, there were significant improvements in TRS motor up to 4-5 years (52.2%; p = 0.032) but this did not reach statistical significance at ≥6 years (46.0%, p = 0.063) in DT, which was comparable to the outcomes in ET. While the improvements in the upper extremity tremor, head tremor, and axial tremor were also comparable between DT and ET throughout the follow-up, the ADL improvements in DT were lost at 2-3 years follow-up. CONCLUSION: Overall, tremor control with VIMDBS in DT and ET was comparable and remained sustained at long term likely related to intervention at the final common node in the pathologic tremor network. However, the long-term ADL improvements in DT were not sustained, possibly due to inadequate control of concomitant dystonia symptoms. These findings from a large cohort of DT indicate that VIM targeting is reasonable if the tremor is considerably more disabling than the dystonic features. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that VIMDBS improves tremor in patients with DT or ET.
Authors: Christopher G Favilla; David Ullman; Aparna Wagle Shukla; Kelly D Foote; Charles E Jacobson; Michael S Okun Journal: Brain Date: 2012-02-17 Impact factor: 13.501
Authors: Takashi Morishita; Kelly D Foote; Ihtsham U Haq; Pamela Zeilman; Charles E Jacobson; Michael S Okun Journal: Stereotact Funct Neurosurg Date: 2010-02-27 Impact factor: 1.875
Authors: Martin M Reich; Joachim Brumberg; Nicolò G Pozzi; Giorgio Marotta; Jonas Roothans; Mattias Åström; Thomas Musacchio; Leonardo Lopiano; Michele Lanotte; Ralph Lehrke; Andreas K Buck; Jens Volkmann; Ioannis U Isaias Journal: Brain Date: 2016-11-01 Impact factor: 13.501
Authors: Johanna Junker; Valerie Brandt; Brian D Berman; Marie Vidailhet; Emmanuel Roze; Anne Weissbach; Cynthia Comella; Irene A Malaty; Joseph Jankovic; Mark S LeDoux; Alfredo Berardelli; Richard Barbano; Stephen G Reich; Joel S Perlmutter; H A Jinnah; Norbert Brüggemann Journal: Neurology Date: 2018-10-19 Impact factor: 9.910
Authors: Takashi Morishita; Justin D Hilliard; Michael S Okun; Dan Neal; Kelsey A Nestor; David Peace; Alden A Hozouri; Mark R Davidson; Francis J Bova; Justin M Sporrer; Genko Oyama; Kelly D Foote Journal: PLoS One Date: 2017-09-13 Impact factor: 3.240
Authors: Robert Francis Dallapiazza; Darrin J Lee; Philippe De Vloo; Anton Fomenko; Clement Hamani; Mojgan Hodaie; Suneil K Kalia; Alfonso Fasano; Andres M Lozano Journal: J Neurol Neurosurg Psychiatry Date: 2018-10-18 Impact factor: 10.154
Authors: Sina R Potel; Sara Marceglia; Sara Meoni; Suneil K Kalia; Rubens G Cury; Elena Moro Journal: Curr Neurol Neurosci Rep Date: 2022-07-15 Impact factor: 6.030
Authors: Joshua K Wong; Christopher W Hess; Leonardo Almeida; Erik H Middlebrooks; Evangelos A Christou; Erin E Patrick; Aparna Wagle Shukla; Kelly D Foote; Michael S Okun Journal: Expert Rev Neurother Date: 2020-03-02 Impact factor: 4.618
Authors: Lisa Hirt; Fabio Grassia; Jeanne Feuerstein; John A Thompson; Steven Ojemann; Drew S Kern Journal: Tremor Other Hyperkinet Mov (N Y) Date: 2021-11-08
Authors: Gabriela S Gilmour; Davide Martino; Karen Hunka; Pia Lawrence; Zelma H T Kiss; Veronica Bruno Journal: Front Neurol Date: 2021-11-29 Impact factor: 4.003
Authors: Nadja Kvernmo; Ane E Konglund; Martin M Reich; Jonas Roothans; Are H Pripp; Espen Dietrichs; Jens Volkmann; Inger Marie Skogseid Journal: Ann Neurol Date: 2022-03-14 Impact factor: 11.274